Lenard M. Lichtenberger

The University of Texas Health Science Center at Houston — United States

Medicine · Health Sciences

46h-index7.1kcitations222works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Helicobacter pylori-related gastroenterology studies(73), Inflammatory mediators and NSAID effects(54), Digestive system and related health(24), Clinical Nutrition and Gastroenterology(23), Drug Transport and Resistance Mechanisms(19)

Publications222 total

Using aspirin to prevent and treat cancer
Inflammopharmacology·2023· 17 cited
Severe COVID-19 outcomes and hematological cancers: the clot thickens—are platelets the culprit?
Translational Cancer Research·2023Open Access
Data from Antitumor and Antiangiogenic Effects of Aspirin-PC in Ovarian Cancer
2023Open Access
Figures for Supplementary Figures 1-7 from Unlocking Aspirin's Chemopreventive Activity: Role of Irreversibly Inhibiting Platelet Cyclooxygenase-1
2023Open Access
Data from Unlocking Aspirin's Chemopreventive Activity: Role of Irreversibly Inhibiting Platelet Cyclooxygenase-1
2023Open Access
Figures for Supplementary Figures 1-7 from Unlocking Aspirin's Chemopreventive Activity: Role of Irreversibly Inhibiting Platelet Cyclooxygenase-1
2023Open Access
Supplementary figures S1-S3 from Antitumor and Antiangiogenic Effects of Aspirin-PC in Ovarian Cancer
2023Open Access
Supplementary figures S1-S3 from Antitumor and Antiangiogenic Effects of Aspirin-PC in Ovarian Cancer
2023Open Access
Supplementary Figures 1-7 from Unlocking Aspirin's Chemopreventive Activity: Role of Irreversibly Inhibiting Platelet Cyclooxygenase-1
2023Open Access
Supplementary Figures 1-7 from Unlocking Aspirin's Chemopreventive Activity: Role of Irreversibly Inhibiting Platelet Cyclooxygenase-1
2023Open Access
Data from Antitumor and Antiangiogenic Effects of Aspirin-PC in Ovarian Cancer
2023Open Access
Data from Unlocking Aspirin's Chemopreventive Activity: Role of Irreversibly Inhibiting Platelet Cyclooxygenase-1
2023Open Access
Development of the PC-NSAID technology: From contact angle to Vazalore®
Drug Discovery Today·2022· 3 cited
A closer look at endothelial injury-induced platelet hyperactivity and the use of aspirin in the treatment of COVID infection
Inflammopharmacology·2022· 3 citedOpen Access
Is COVID-19–Induced Platelet Activation a Cause of Concern for Patients with Cancer?
Cancer Research·2020· 14 citedOpen Access
Expression of Intrinsic Factor in Rat and Murine Gastric Mucosal Cell Lineages Is Modified by Inflammation
UNC Libraries·2020· 1 citedOpen Access
Sulindac plus a phospholipid is effective for polyp reduction and safer than sulindac alone in a mouse model of colorectal cancer development
BMC Cancer·2020· 16 citedOpen Access
Abstract 1: Sulindac plus phospholipid is effective for polyp reduction and safer than sulindac alone
Cancer Research·2020
Growth inhibitory effects of PC‑NSAIDs on human breast cancer subtypes in cell culture
Oncology Letters·2019· 5 citedOpen Access
Are Platelets the Primary Target of Aspirin's Remarkable Anticancer Activity?
Cancer Research·2019· 43 citedOpen Access
page 1 of 12Next →

Frequent Co-authors

Elizabeth J. Dial(16), Jimmy J. Romero(8), B. A. Hills(5), Yong Zhou(5), Leonard R. Johnson(4), J.J. Romero(4), Marie‐Noëlle Giraud(3), Bruce D. Butler(3), Philip J. Goddard(3), Sudershan K. Sanduja(3), Upendra Marathi(3), Juan Lechago(3), Edward M. Copeland(2), Stanley J. Dudrick(2), Gilbert A. Castro(2), Lynne A. Graziani(2), John F. Hancock(2), Ya-Chu J. Kao(2), Bhupinderjit S. Anand(2), Rebecca Darling(2)